$599

Novo’s IL-6 Ph3 CVOT Posted to CT.gov; Additional Diamyd T1DM Vaccine Analyses

Two cardiometabolic news items have been observed: Novo Nordisk has initiated the Ph3 ziltivekimab CVOT (ZEUS) in 6,200 adults with established ASCVD, CKD, and systemic inflammation; and Diamyd announced the results from two new analyses on the meta-analysis dataset from the four previous trials evaluating the efficacy and safety of the Diamyd vaccine in T1DM. Below, FENIX provides highlights and insights for the respective news items.

This content is for members only.
Register
Already a member? Log in here